Latest Breaking News On - Head of retinal health at boehringer ingelheim - Page 1 : comparemela.com

​​Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia​

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and .

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ...

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia GlobeNewswire May 06, 2024 Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found.

Boehringer Ingelheim Shares Positive Results from the First Study Worldwide in Diabetic Macular Ischemia

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss